LACEY SANCHEZ: Open Payments
NPI 1841570272 · FORT COLLINS, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$569 in 27 payments from 11 companies in 2025. Trend: 2023 $1,038 · 2024 $856 · 2025 $569
Food & beverage: $535Education: $34
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 9 | $213 |
| CSL Behring | 3 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $57 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $47 |
| Lilly USA, LLC | 2 | $39 |
| Regeneron Healthcare Solutions, Inc. | 2 | $38 |
| Novartis Pharmaceuticals Corporation | 2 | $36 |
| Amgen Inc. | 1 | $34 |
| Grifols USA, LLC | 1 | $17 |
| Incyte Corporation | 1 | $16 |
Products named: NUCALA, Hizentra, TAKHZYRO, NEFFY, EBGLYSS, DUPIXENT, Rhapsido, Xembify.
Industry payments across CO — which companies pay providers there.
